Regulation of transforming growth factor-β type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues

Gengfei Wu, Robert S. Fan, Wenhui Li, Venkateswarlu Srinivas, Michael G Brattain

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

In view of the tumor suppressor role of the transforming growth factor- β (TGFβ) type II receptor (RII), the identification and characterization of agents that can induce the expression of this receptor are of potential importance to the development of chemoprevention approaches as well as treatment of cancer. To date, the identification of exogenous agents that control RII expression has been rare. We demonstrated that proliferation of MCF-7 early passage cells (MCF-7 E), which express RII and are sensitive to TGFβ growth inhibition activity, was significantly inhibited by vitamin D3 and its analogue EB1089. In contrast, proliferation of MCF-7 late passage cells (MCF-7 L), which have lost cell surface RII and are resistant to TGFβ, was not affected by these two compounds. TGFβ-neutralizing antibody was able to block the inhibitory effect on MCF-7 cells by these compounds, indicating that treatment induced autocrine-negative TGFβ activity. An RNase protection assay showed approximately a 3-fold induction of the RII mRNA, while a receptor cross-linking assay revealed a 3-4-fold induction of the RII protein. In contrast, there was no change in either RII mRNA or protein in the MCF-7 cells.

Original languageEnglish (US)
Pages (from-to)7749-7756
Number of pages8
JournalJournal of Biological Chemistry
Volume273
Issue number13
DOIs
StatePublished - Mar 27 1998

Fingerprint

Growth Factor Receptors
Cholecalciferol
MCF-7 Cells
Transforming Growth Factors
Breast Neoplasms
Assays
Messenger RNA
Chemoprevention
Ribonucleases
Neutralizing Antibodies
Tumors
Neoplasms
Proteins
Therapeutics
Growth

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Regulation of transforming growth factor-β type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues. / Wu, Gengfei; Fan, Robert S.; Li, Wenhui; Srinivas, Venkateswarlu; Brattain, Michael G.

In: Journal of Biological Chemistry, Vol. 273, No. 13, 27.03.1998, p. 7749-7756.

Research output: Contribution to journalArticle

Wu, Gengfei ; Fan, Robert S. ; Li, Wenhui ; Srinivas, Venkateswarlu ; Brattain, Michael G. / Regulation of transforming growth factor-β type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues. In: Journal of Biological Chemistry. 1998 ; Vol. 273, No. 13. pp. 7749-7756.
@article{e24e3675917b4e30874ee87cbec51407,
title = "Regulation of transforming growth factor-β type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues",
abstract = "In view of the tumor suppressor role of the transforming growth factor- β (TGFβ) type II receptor (RII), the identification and characterization of agents that can induce the expression of this receptor are of potential importance to the development of chemoprevention approaches as well as treatment of cancer. To date, the identification of exogenous agents that control RII expression has been rare. We demonstrated that proliferation of MCF-7 early passage cells (MCF-7 E), which express RII and are sensitive to TGFβ growth inhibition activity, was significantly inhibited by vitamin D3 and its analogue EB1089. In contrast, proliferation of MCF-7 late passage cells (MCF-7 L), which have lost cell surface RII and are resistant to TGFβ, was not affected by these two compounds. TGFβ-neutralizing antibody was able to block the inhibitory effect on MCF-7 cells by these compounds, indicating that treatment induced autocrine-negative TGFβ activity. An RNase protection assay showed approximately a 3-fold induction of the RII mRNA, while a receptor cross-linking assay revealed a 3-4-fold induction of the RII protein. In contrast, there was no change in either RII mRNA or protein in the MCF-7 cells.",
author = "Gengfei Wu and Fan, {Robert S.} and Wenhui Li and Venkateswarlu Srinivas and Brattain, {Michael G}",
year = "1998",
month = "3",
day = "27",
doi = "10.1074/jbc.273.13.7749",
language = "English (US)",
volume = "273",
pages = "7749--7756",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "13",

}

TY - JOUR

T1 - Regulation of transforming growth factor-β type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues

AU - Wu, Gengfei

AU - Fan, Robert S.

AU - Li, Wenhui

AU - Srinivas, Venkateswarlu

AU - Brattain, Michael G

PY - 1998/3/27

Y1 - 1998/3/27

N2 - In view of the tumor suppressor role of the transforming growth factor- β (TGFβ) type II receptor (RII), the identification and characterization of agents that can induce the expression of this receptor are of potential importance to the development of chemoprevention approaches as well as treatment of cancer. To date, the identification of exogenous agents that control RII expression has been rare. We demonstrated that proliferation of MCF-7 early passage cells (MCF-7 E), which express RII and are sensitive to TGFβ growth inhibition activity, was significantly inhibited by vitamin D3 and its analogue EB1089. In contrast, proliferation of MCF-7 late passage cells (MCF-7 L), which have lost cell surface RII and are resistant to TGFβ, was not affected by these two compounds. TGFβ-neutralizing antibody was able to block the inhibitory effect on MCF-7 cells by these compounds, indicating that treatment induced autocrine-negative TGFβ activity. An RNase protection assay showed approximately a 3-fold induction of the RII mRNA, while a receptor cross-linking assay revealed a 3-4-fold induction of the RII protein. In contrast, there was no change in either RII mRNA or protein in the MCF-7 cells.

AB - In view of the tumor suppressor role of the transforming growth factor- β (TGFβ) type II receptor (RII), the identification and characterization of agents that can induce the expression of this receptor are of potential importance to the development of chemoprevention approaches as well as treatment of cancer. To date, the identification of exogenous agents that control RII expression has been rare. We demonstrated that proliferation of MCF-7 early passage cells (MCF-7 E), which express RII and are sensitive to TGFβ growth inhibition activity, was significantly inhibited by vitamin D3 and its analogue EB1089. In contrast, proliferation of MCF-7 late passage cells (MCF-7 L), which have lost cell surface RII and are resistant to TGFβ, was not affected by these two compounds. TGFβ-neutralizing antibody was able to block the inhibitory effect on MCF-7 cells by these compounds, indicating that treatment induced autocrine-negative TGFβ activity. An RNase protection assay showed approximately a 3-fold induction of the RII mRNA, while a receptor cross-linking assay revealed a 3-4-fold induction of the RII protein. In contrast, there was no change in either RII mRNA or protein in the MCF-7 cells.

UR - http://www.scopus.com/inward/record.url?scp=0032571389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032571389&partnerID=8YFLogxK

U2 - 10.1074/jbc.273.13.7749

DO - 10.1074/jbc.273.13.7749

M3 - Article

VL - 273

SP - 7749

EP - 7756

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 13

ER -